Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00177346
Other study ID # MakarounIDE
Secondary ID 0
Status Completed
Phase N/A
First received September 12, 2005
Last updated January 5, 2016
Start date October 2003
Est. completion date January 2007

Study information

Verified date January 2016
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate carotid artery stenting (CAS) with and without cerebral protection (CP) to determine if CP improves safety and effectiveness of CAS.


Description:

This study is a single center, prospective, randomized trial evaluating the safety and effectiveness of CAS with and without CP. The study population will be comprised of subjects with atherosclerotic, post endarterectomy restenotic or other obstructive lesions in native carotid arteries. Other carotid artery pathology not amenable to surgical repair (for example carotid artery dissection) will also be considered. Subjects at high risk for complications from standard CEA will be the target population for this study. High risk status will be confirmed by two physicians, one of whom is a vascular surgeon. Both symptomatic and asymptomatic subjects will be enrolled. This will ensure that the proportion of symptomatic subjects is the same in the two arms of the study. "Symptomatic" is defined in the exclusion criteria. The expected duration of this clinical trial is 3 years.

In this study there are there are two arms that a subject may be randomized to:

Group1: CAS with the use of the RX ACCUNET Group 2: CAS without the use of the RX ACCUNET This study has been designed to test whether the addition of CP enhances the safety and effectiveness of CAS.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date January 2007
Est. primary completion date January 2007
Accepts healthy volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- To participate in this study, the subject MUST have all of the following for inclusion in the study:

• The subject (male or non-pregnant female) must be > 18 years of age.

• The subject should have a stenosis in the common or internal carotid artery of at least 70% determined by one of the modalities listed below.

• The subject should be considered a relatively high risk for carotid endarterectomy. This determination has to be made and documented by two physicians, at least one of who must be a vascular surgeon acting as an investigator on this trial. High risk considerations should include at least one of the following:

1. Cardiac dysfunction. NYHA class III or above, compensated or active congestive heart failure (CHF), incomplete coronary revascularization, ejection fraction of <35%, pulmonary hypertension, or recommendation of a cardiologist against open CEA.

2. Pulmonary dysfunction, history of respiratory failure, severe chronic obstructive pulmonary Disease (COPD) on bronchodilators or recommendation of a pulmonary specialist against open CEA.

3. Multi-system dysfunction, defined as any combination of medical problems in three distinct systems.

4. Anatomic issues: previous CEA or neck dissection, neck irradiation, inaccessible lesions, neck fusion or other anatomic considerations increasing the risk of CEA.

5. Age >80 AND symptomatic (defined below)

6. General debilitation documented by the subject's primary physician.

7. Increased anesthetic risk as documented by an anesthesiologist.

- Subjects can be either clinically symptomatic or asymptomatic (less than 80 years of age). Symptomatic subjects will have experienced an event within the previous 120 days in the ipsilateral carotid artery distribution. The event will be classified as either 1) one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or 2) one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event).

**Patients with major non-hemorrhagic strokes will be included if their clinical status has been stable for 5 days (based on an exam performed by a neurologist participating as a Co-Investigator in this trial).

- If an angiogram is performed to qualify the subject, it should be as recent as feasible and will not be acceptable if done > 120 days from study entry. Angiograms from other institutions will be acceptable.

- Other non-invasive qualifying imaging modalities include:

1. Duplex ultrasound (DU) performed at UPMC Presbyterian or Shadyside hospitals.

2. Magnetic Resonance Angiography (MRA) performed at UPMC Presbyterian or Shadyside hospitals.

3. Computed Tomographic Angiography (CTA) performed at UPMC Presbyterian or Shadyside hospitals.

- The degree of stenosis from these non-invasive studies has to be confirmed on the pre-deployment diagnostic angiography prior to proceeding with stent deployment.

- However, if two of the non-invasive studies listed above report a stenosis of >70%, AND the pre-deployment angiogram reveals a 50 -70% stenosis, the patient will be randomized and entered into the trial as the angiogram can on occasion underestimate the stenosis.

- Female subjects of childbearing potential must have a documented negative pregnancy test during the index hospitalization.

- The subject must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board or Medical Ethics Committee.

- If a patient's creatinine is 3.5 or greater, their nephrologist must clear them to participate in the trial.

Exclusion Criteria:

- To participate in this study, the subject may NOT HAVE any of the following at enrollment to the study:

- The subject has had an intracranial hemorrhage, hemorrhagic stroke, or any stroke with mass effect demonstrated on CT scan or MRI within 30 days of the index procedure.

- The subject has a persisting ischemic stroke (defined as either a score > 15 on the NIH stroke scale, a Rankin score > 3 or a Barthel score < 60 measured within one week prior to study entry).

- The subject has an intracranial mass lesion (i.e., abscess, tumor, or other infection).

- The subject has known allergies to heparin, to both ticlopidine and clopidogrel or to metals used in stents.

- There is any visual angiographic evidence of intraluminal thrombus thought to increase the risk of plaque fragmentation and distal embolization.

- The subject has peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding use of catheter-based techniques required for successful results.

- The subject, if female, has a positive pregnancy test.

- The subject has an arterio-venous malformation in the territory of the target carotid artery.

- Subjects with highly calcified lesions resistant to predilation by PTA

- The subject has unstable angina (defined as Class IV or at rest), evolving MI or recent MI (within 14 days).

- The subject has any condition that precludes adequate local hemostasis.

- Patients who are not candidates for MRI scanning (pacemaker, etc).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
CAS with cerebral protection

CAS without cerebral protection


Locations

Country Name City State
United States University of Pittsburgh Medical Center Presbyterian &Shadyside Hospitals Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Endpoint
Primary Safety: The 30-day composite of stroke or death,
Primary Effectiveness: The percentage of subjects who show evidence of new ischemic injury on diffusion MRI imaging, as well as the amount of infarcted tissue
Secondary Secondary Endpoints
Secondary Successful stent deployment at the target lesion,
Secondary Successful CP device deployment and retrieval,
Secondary Successful resolution of the stenosis (<30% residual stenosis) determined by angiography immediately post-stent placement,
Secondary Access site vascular complications, defined as need for surgical repair or blood transfusion,
Secondary Restenosis (>50% diameter reduction) rates both in-stent or of the adjacent artery determined by carotid ultrasound imaging at 1 year post-procedure,
Secondary Ipsilateral neurologic deficits on neurologic assessments at 24 hours and 30 days post-procedure.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931161 - Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) Phase 4
Recruiting NCT03353103 - Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy Phase 2
Completed NCT03996148 - Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques Phase 4
Completed NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Completed NCT00318851 - Carotid Artery Stenting With Protection Registry Phase 3
Active, not recruiting NCT05293067 - Troponin In Carotid Revascularization
Completed NCT03133429 - Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation. N/A
Recruiting NCT01440036 - The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque N/A
Completed NCT00417963 - ViVEXX Carotid Revascularization Trial (VIVA) Phase 3
Recruiting NCT05574972 - Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial) N/A
Recruiting NCT02476396 - Structural Stability of Carotid Plaque and Symptomatology
Completed NCT05451485 - VFI in Healthy Vessels
Recruiting NCT06033963 - Safety and Efficacy of Remote Ischemic Conditioning in Patients With Carotid Artery Stenosis Receiving Carotid EndArterectomy N/A
Not yet recruiting NCT02224209 - Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Phase 4
Completed NCT02006095 - Neuroimaging Correlates of Memory Decline Following Carotid Interventions
Terminated NCT01236508 - Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease Phase 4
Recruiting NCT05126238 - A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction Phase 3
Recruiting NCT06170580 - Improved Image Quality for Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound FLOW Imaging
Recruiting NCT05800821 - Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning